Results 101 to 110 of about 24,468 (197)
Depot Medroxyprogesterone Acetate in Combination with a Twice-Daily Lopinavir-Ritonavir-Based Regimen in HIV-Infected Women Showed Effective Contraception and a Lack of Clinically Significant Interactions, with Good Safety and Tolerability: Results of the ACTG 5283 Study
Antimicrobial Agents and Chemotherapy, 2015 Amneris Luque, Susan E. Cohn, J. Park, Y. Cramer, A. Weinberg, E. Livingston, K. Klingman, F. Aweeka, D. Watts, AE Luque, SE Cohn, P. J.-G. +11 moresemanticscholar +1 more sourceElagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis
Reproductive Sciences, 2014 B. Carr, W. Paul Dmowski, Christopher F. O’Brien, P. Jiang, Joshua Burke, R. Jimenez, E. Garner, K. Chwalisz +7 moresemanticscholar +1 more sourceLong-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells.
Journal of Infectious Diseases, 2014 C. Mitchell, L. McLemore, Katharine Westerberg, Rena D. Astronomo, K. Smythe, C. Gardella, M. Mack, A. Magaret, D. Patton, K. Agnew, M. McElrath, F. Hladik, D. Eschenbach +12 moresemanticscholar +1 more source